Allosteric Regulation Calculators

0 calculators tagged with “Allosteric Regulation”

Allosteric regulation is the modulation of protein function through binding of a ligand (effector) at a site other than the active site — the allosteric site. Binding of an allosteric effector induces conformational changes that alter the protein's activity, affinity for substrate, or interactions with other molecules. Allosteric activation increases activity; allosteric inhibition decreases it. Allosteric regulation is a key control mechanism in metabolic pathways (feedback inhibition), signal transduction, and cooperative oxygen binding in hemoglobin. It is also an important target for drug design, as allosteric sites offer high selectivity potential.

All Calculators

No calculators found for this topic.

Types of Allosteric Regulation

  • Allosteric activation: Effector binding increases enzyme activity or substrate affinity. Example: AMP activates phosphofructokinase-1 (PFK-1), accelerating glycolysis when energy is low.
  • Allosteric inhibition: Effector binding decreases activity. Example: ATP inhibits PFK-1 (feedback inhibition when energy is high); end-product inhibition in biosynthetic pathways.
  • Homotropic allostery: The substrate itself is the allosteric effector (cooperative binding, as in hemoglobin-O₂)
  • Heterotropic allostery: A different molecule modulates activity (2,3-BPG modulating hemoglobin-O₂ affinity)

T-State and R-State (MWC Model)

The Monod-Wyman-Changeux (MWC) concerted model: oligomeric proteins exist in two states — T (tense, low affinity) and R (relaxed, high affinity) — in equilibrium. Allosteric activators shift the equilibrium toward R; inhibitors toward T. The KNF (induced fit / sequential) model alternatively proposes that each subunit changes conformation individually upon ligand binding.

Cooperativity and Hill Coefficient

Cooperative binding: binding one ligand increases affinity for subsequent ligands. Hemoglobin O₂ binding: Hill coefficient n ≈ 2.8. v = Vmax × [S]^n / (K₀.₅^n + [S]^n). n = 1: no cooperativity (Michaelis-Menten); n > 1: positive cooperativity (sigmoidal curve); n < 1: negative cooperativity.

Allosteric Drug Design

Allosteric drugs bind sites distinct from the orthosteric (substrate/ligand) site. Advantages: selectivity (allosteric sites are less conserved than active sites); 'ceiling' effect (activity is modulated, not completely blocked — reducing toxicity risk); ability to modulate rather than block. Examples: benzodiazepines (allosteric modulators of GABA_A receptor); maraviroc (allosteric HIV CCR5 co-receptor inhibitor); MEK inhibitors (allosteric kinase inhibitors).

Glossary

Allosteric Regulation
Modulation of protein function by a ligand binding at a site other than the active site; induces conformational changes that alter activity or substrate affinity; includes activation and inhibition.
Hill Coefficient (n)
A measure of cooperativity: n=1 = no cooperativity (Michaelis-Menten); n>1 = positive cooperativity (sigmoidal curve, e.g., hemoglobin n≈2.8); n<1 = negative cooperativity.
Feedback Inhibition
Allosteric inhibition of an early pathway enzyme by the end product; prevents overproduction; a key metabolic control mechanism (e.g., threonine inhibits threonine deaminase).

Frequently Asked Questions

Allosteric regulation occurs when a molecule (effector) binds to a site other than the active site, inducing conformational changes that alter the protein's activity or ligand affinity. Allosteric activators increase activity (AMP activates PFK-1); allosteric inhibitors decrease it (ATP inhibits PFK-1). Unlike competitive inhibitors, allosteric inhibitors cannot be overcome by increasing substrate concentration — they change the protein's shape, not its substrate binding site. Allosteric regulation is a key mechanism for feedback control of metabolic pathways: the end product of a pathway inhibits the first committed enzyme, preventing overproduction.

Homotropic allostery: the substrate itself acts as the allosteric effector — binding at one site increases (or decreases) affinity at other sites. This causes cooperative binding and produces sigmoidal saturation curves. Hemoglobin is the classic example: binding of O₂ to one heme increases affinity at the other three heme groups. Heterotropic allostery: a molecule different from the substrate modulates activity. 2,3-BPG (2,3-bisphosphoglycerate) is a heterotropic allosteric inhibitor of hemoglobin that decreases O₂ affinity by stabilizing the T-state, facilitating O₂ delivery to tissues.

Cooperativity describes how binding at one site influences affinity at other sites. Positive cooperativity (n > 1): each ligand binding increases affinity for the next — produces sigmoidal saturation curve. Negative cooperativity (n < 1): each binding decreases affinity for the next. The Hill coefficient n quantifies the degree of cooperativity: n = 1 is no cooperativity (Michaelis-Menten hyperbola); n = 2.8 for hemoglobin-O₂; n → ∞ would be perfectly cooperative (all-or-none). The Hill equation: v = Vmax × [S]^n / (K₀.₅^n + [S]^n). The switch-like behavior of cooperative proteins makes them ideal for signal-response functions in cells.

Allosteric drugs bind sites other than the active site, offering several advantages: (1) Selectivity — allosteric sites are less evolutionarily conserved than active sites (where substrates bind), allowing more target-specific drugs with fewer off-target effects. (2) Modulatory ceiling — allosteric modulators tune activity rather than fully blocking it, which can improve safety for targets where complete inhibition is harmful. (3) Independence from substrate competition — not displaced by high substrate concentrations unlike competitive inhibitors. Examples: benzodiazepines (positive allosteric modulators of GABA_A Cl⁻ channel, enhancing GABA effect); maraviroc (binds allosteric site of CCR5 preventing HIV gp120 binding); cobimetinib (allosteric MEK kinase inhibitor).